2016
DOI: 10.3899/jrheum.151296
|View full text |Cite
|
Sign up to set email alerts
|

The Need for Biological Outcomes for Biological Drugs in Psoriatic Arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
4

Relationship

4
0

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 29 publications
(27 reference statements)
0
3
0
Order By: Relevance
“…[H1] Dactylitis scoring methods In addition to dactylitis forming one of the classification criteria components of CASPAR for PsA 5 , the number of PsA clinical outcome measures has increased rapidly over the past few years 18 . Dactylitis scores are important inclusions in most of these measures, including the Composite Psoriatic Disease Activity Index (CPDAI) and the Psoriatic Arthritis Disease Activity Score (PASDAS) 19,20 .…”
mentioning
confidence: 99%
“…[H1] Dactylitis scoring methods In addition to dactylitis forming one of the classification criteria components of CASPAR for PsA 5 , the number of PsA clinical outcome measures has increased rapidly over the past few years 18 . Dactylitis scores are important inclusions in most of these measures, including the Composite Psoriatic Disease Activity Index (CPDAI) and the Psoriatic Arthritis Disease Activity Score (PASDAS) 19,20 .…”
mentioning
confidence: 99%
“…Dr Tan highlighted the two main areas of application for imaging in SpA, namely in clinical practice and in the research setting [ 16–18 ]. The clinical use of imaging in SpA is supported by EULAR, who outlined its usefulness; in particular, the use of MRI and US [ 19 ].…”
Section: Lecturesmentioning
confidence: 99%
“…The challenges of diagnosis in early PsA are not confined to the heterogeneity of disease, which is evident from the variety of outcome measures available (2). In contrast to RA, there are no biomarkers such as anti-citrullinated peptide antibody (ACPA) or rheumatoid factor (RF) to identify early PsA and therefore diagnosis is dependent upon identification of specific clinical features.…”
Section: Introductionmentioning
confidence: 99%